ANGPTL3 and hyperlipidemia: However, because ANGPTL3 inhibitors are being developed to treat preexisting hyperlipidemia in broad populations at risk for ASCVD, it is of interest to determine the effect of ANGPTL3 inhibition on not only HDL-C but also HDL function, particularly RCT.